Supplementary Figure 1 from Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
Seiji Yano(Kanazawa University Hospital), Saburo Sone(Io Therapeutics (United States)), Yasuhiko Nishioka(Tokushima University), Hisanori Uehara(Tokushima University Hospital), Yasushi Yatabe(University Hospital Münster), Hirokazu Ogino(Tokushima University), Kunio Matsumoto(Kanazawa University), Tetsuya Mitsudomi(Kindai University), Qi Li, Wei Wang(Nanfang Hospital), Masaki Hanibuchi(Tokushima University), Takahiro Nakamura(Kyoto University), Soji Kakiuchi(Tokushima Prefectural Central Hospital), Toshikazu Nakamura(The University of Osaka), Haruko Sakurama(Kanazawa University)
Cited by 0
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Reduced Expression of the <b> <i>let-7</i> </b> MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival
|Cancer Research|2004|2.4k